The tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) has gained much attention as a possible therapeutic reagent for the treatment of tumors, as TRAIL was originally described to induce apoptosis specifically in cancer cells, but not in normal cells. Fibroblast-like synoviocytes (FLS) in rheumatoid arthritis (RA) patients exhibit tumor-like features and we have described earlier that TRAIL induces apoptosis only in a subset of RA FLS, but an induction of proliferation in the surviving cells. This observation corresponds to the pleiotropic effects of TRAIL observed on primary human tumor cells. Here, we describe that the PI3 kinase/Akt-signaling pathway, but not that of the MAP kinases ERK and p38, protects RA FLS from TRAIL-induced apoptosis by modulating the expression of the cell survival regulators p21, XIAP, Mcl-1 and RIP. Moreover, we found that not only TRAIL-induced apoptosis, but also TRAIL-triggered proliferation in RA FLS is mediated by caspases with a crucial role for caspase 8. TRAIL was found to induce degradation of p21 and p27 that was caspase-dependent, but independent of the ERK, p38 and PI3 kinase/Akt-signaling pathways. The finding that TRAIL-triggered proliferation and apoptosis share intracellular routes has to be taken in consideration in defining therapeutic strategies on the basis of the administration of TRAIL. In recent years, considerable attention has been focused on the potential benefits of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) in cancer therapy, as a broad range of cancer cells are sensitive to TRAIL-induced apoptosis (reviewed in 1 ). In addition, the use of TRAIL in combination with chemotherapeutic agents or irradiation strengthens its apoptotic effects and frequently sensitizes the otherwise TRAIL-resistant tumor cells. It is important that TRAIL does not seem to be toxic to normal cells, as TRAIL exposure shows no toxic side effects of therapeutically relevant doses in primates.
In recent years, considerable attention has been focused on the potential benefits of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) in cancer therapy, as a broad range of cancer cells are sensitive to TRAIL-induced apoptosis (reviewed in 1 ) . In addition, the use of TRAIL in combination with chemotherapeutic agents or irradiation strengthens its apoptotic effects and frequently sensitizes the otherwise TRAIL-resistant tumor cells. It is important that TRAIL does not seem to be toxic to normal cells, as TRAIL exposure shows no toxic side effects of therapeutically relevant doses in primates.
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand can interact with five different receptors: four membrane-anchored receptors TRAIL-R1 (DR4), TRAIL-R2 (DR5), TRAIL-R3 (DcR1) and TRAIL-R4 (DcR2) and a soluble decoy receptor osteoprotegerin. The receptors TRAIL-R1 and -R2 contain an intracellular cytoplasmic sequence motif, known as the death domain (DD), and can induce apoptosis through activation of caspases (reviewed in 2 ). Nevertheless, TRAIL-receptors R1 and R2 not only trigger apoptosis, but also proliferation and differentiation depending on the cell type (reviewed in 2 ). This phenomenon has been described for several other members of the TNF family and it is thought that one pathway potentially pre-dominates, but that a build-up of intracellular regulators can flick the switch from cell death to proliferation and vice versa. 2, 3 For example, TRAIL has been shown to promote cell survival and proliferation of endothelial and vascular smooth muscle cells 4, 5 and to regulate erythroid and monocytic maturation. 6 Evidence is accumulating that TRAIL has multiple effects also on tumor cells. For example, Ehrhardt et al. 7 analyzed the effect of TRAIL on primary cells of children with untreated acute leukemia. They observed that TRAIL induced apoptosis in only 50% of the leukemia cell samples tested, but survival or proliferation in the remaining samples. 7 Concurring with this report is a study describing that the effect of TRAIL on leukemia cells can be either pro-apoptotic or pro-proliferative. 8 A more recent publication reported that TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma in SCID/beige mice. 9 All these findings challenge the proposed strategy to use TRAIL for targeting tumor cells. To overcome this problem, it has been suggested to sensitize tumor cells for TRAIL-induced apoptosis by blocking the proliferative signaling pathways. For this, it is essential to characterize the respective pathways triggered by TRAIL.
Rheumatoid arthritis (RA) is characterized by the pseudotumoral expansion of synovial tissue that lines the capsule of a joint and is composed of differentiated macrophages and fibroblast-like synoviocytes (FLS). The FLS play a crucial role in the physiopathology of RA, as they invade and finally destroy the joint structure. The proliferation of RA FLS is considered to be pseudo-tumoral, as RA FLS proliferate in an anchorage-independent manner, lack contact inhibition, and express oncogenes and cell cycle proteins indicative of transformation. 10 Several primary tumors are difficult to maintain in cell cultures and require special conditions. In contrast, the tumor-like features exhibited by RA FLS can be easily mimicked in vitro, as RA FLS grow under standard cell culture conditions. This, together with our access to synovial tissue isolated from the RA patients, led us to choose RA FLS as the cellular model to investigate the therapeutic potential of TRAIL on tumor tissues.
We have described earlier that TRAIL induces apoptosis only in a subset of RA FLS that is followed by an induction of proliferation in the surviving cells. 11 This suggests that FLS of RA patients consists of different subpopulations according to their different TRAIL responses. The observed dual functionality of TRAIL on RA FLS concurs with the earlier reported pleiotropic responses of TRAIL in primary human tumor cells and underlines that the pseudo-tumoral expansion of RA FLS is a suitable model to characterize the signaling pathways triggered by TRAIL. The molecular differences of the signaling pathways mediating TRAIL-induced apoptosis and proliferation are still poorly understood. The aim of this study was to better understand the molecular basis of TRAIL-triggered signaling pathways in RA FLS.
Results
The PI3 kinase/Akt-signaling pathway, but not the MAP kinases ERK and p38, protect RA FLS from TRAILinduced apoptosis. We have described earlier that TRAIL activates the MAP kinases ERK and p38, as well as the serine/ threonine kinase Akt, with kinetics similar to that observed for TNF-a-driven proliferation of RA FLS. 11 To test whether either of these pathways is also implicated in TRAIL-induced apoptosis, we used specific inhibitors targeting PI3 kinase (LY294002), ERK1/2 (PD98059) and p38 (SB203580). For this, RA FLS from five different patients were pretreated with the specific inhibitors at different concentrations or with solvent (DMSO) alone, for 45 min before the addition of TRAIL (1 nM). TRAIL (1 nM) was sufficient to induce maximal proliferation and apoptosis in RA FLS (Figure 1 ). Proliferation of RA FLS was determined by [ 3 H] thymidine incorporation after 72 h of TRAIL exposure, revealing that addition of each kinase inhibitor diminished TRAIL-induced proliferation in a dosedependent manner (data not shown), in agreement with our earlier findings. 11 To measure cell death, cells were treated for 24 h with TRAIL and analyzed by Annexin V staining/TO-PRO-3 uptake. Addition of the PI3 kinase inhibitor LY294002 sensitized RA FLS towards TRAIL-induced apoptosis in a dose-dependent manner, whereas ERK and p38 inhibitors displayed no significant effect on cell viability (Figure 2a ). This 
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The pleiotropic effect of TRAIL is mediated by caspases R Audo et al sensitization was not because of an altered expression pattern of TRAIL receptors 1 and 2 (data not shown). By using the structurally unrelated PI3 kinase inhibitors, wortmannin and PI-103, we could confirm that the observed effect of LY294002 is indeed because of blocking of PI3 kinase ( Figure 2b ). In addition, we have used a chemical inhibitor for Akt (protein kinase B), which is activated by PI3 kinases, displaying increased TRAIL-induced apoptosis similar to that observed for the PI3 kinase inhibitors (Figure 2b ).
We next tested whether exposure of RA FLS to the PI3 kinase inhibitor LY294002 altered the expression levels of well-established regulators of cell survival including XIAP, PTEN, Mcl-1, RIP, p21 and p27. Western blot analysis displayed altered expression levels of XIAP, Mcl-1, RIP and p21 in LY294002-treated RA FLS, whereas expression of p27 and PTEN only moderately decreased (Figure 2c ). Expression levels of p21 and p27 were already affected after 6 h of LY290042 exposure, whereas those of XIAP, PTEN, Mcl-1 and RIP were only observed after 24 h of treatment. In TRAIL-treated cells, levels of XIAP, Mcl-1 and RIP were already decreased after 6 h of LY290042 exposure (Figure 2d ), suggesting that PI3 kinase activation may protect these proteins from TRAIL-induced degradation. Noteworthy, p21 levels were elevated after 6 h, but decreased after 24 h of co-treatment with LY290042 and TRAIL. This observation indicates that PI3 kinase inhibition only temporarily protects TRAIL-induced p21 degradation (see below).
Thus, whereas the ERK, p38 and PI3 kinase/Akt-signaling pathways are all involved in TRAIL-induced proliferation, only PI3 kinase/Akt protects RA FLS from TRAIL-triggered apoptosis, possibly by modulating the expression levels of p21, XIAP, Mcl-1 and RIP. (Figure 3a) , whereas the control inhibitor z-FA-fmk had no effect on RA FLS survival (data not shown). It is surprising that treatment with z-VAD-fmk also decreased TRAIL-induced proliferation of RA FLS, and the addition of 5 mM of z-VAD-fmk almost completely abrogated TRAIL-induced proliferation ( Figure 3b ). Similar results were obtained when cells were pretreated with the pan-caspase inhibitor Q-VD-OPh before TRAIL treatment 14 (data not shown). These data suggest that in RA FLS caspases play a role in both TRAIL-driven apoptosis and proliferation.
We have reported earlier that the cleaved forms of caspases 3, 8 and 9 are detectable in cell lysates of RA FLS treated with TRAIL.
14 To determine their exact contribution to TRAIL-induced apoptosis and proliferation, we used specific inhibitors for each one. All three caspases inhibitors significantly diminished TRAIL-induced apoptosis at 5 mM, though less efficiently as the pan-caspase inhibitor ( Figure 4a ). The specific inhibitors for caspases 3 and 8 also modulated TRAIL-induced proliferation (Figure 4b ). However, these effects were dependent on the concentration of the respective inhibitor used. Low concentrations of the inhibitors for caspase 3 and 8 increased TRAIL-stimulated proliferation of RA FLS, whereas they decreased proliferation when added at concentration of 50 mM (Figure 4b ). Blocking of TRAILinduced proliferation was more efficient with the caspase 8 inhibitor, which showed an effect at a concentration of 20 mM (Figure 4c ). The specific caspase 9 inhibitor had no significant effect on TRAIL-induced proliferation (Figure 4b ), but was toxic at a concentration of 50 mM (as detected using MTT assay, data not shown). Treatment of RA FLS with the highest non-toxic concentration of the specific caspase 9 inhibitor, that is, 20 mM, induced a small, but not significant reduction of TRAIL-induced proliferation (Figure 4c) .
To further assess the contribution of individual caspases we used small interfering RNAs (siRNA) against caspases 3, 8 and 9 as an additional approach. As shown in Figures 4d-g, only siRNA silencing of caspase 8, but not of caspases 3 and 9, was able to diminish TRAIL-induced apoptosis and proliferation. The efficiency of caspases silencing in RA FLS is shown in Figure 4h . Taken together, these data indicate that caspases mediate both TRAIL-induced apoptosis as well as proliferation in RA FLS. Caspase 8 in particular seems to play an important role in both the processes.
TRAIL induces caspase-dependent degradation of the cell cycle inhibitors p21 and p27. As described earlier, TRAIL induces RA FLS proliferation through activation of the MAP kinases ERK and p38, as well as the PI3 kinase/Akt pathway. 11 We therefore tested whether caspases participate in the activation of these pathways. The presence of the pan-caspase inhibitor z-VAD-fmk did not seem to affect TRAIL-induced phosphorylation (and thus activation) of either Akt or the MAP kinases ERK and p38 ( Figure 5 ). However, we did observe that addition of the pancaspase inhibitor significantly induced phosphorylation of MAP kinases ERK and p38, as well as Akt in unstimulated RA FLS. This effect of z-VAD-fmk was dose dependent (data not shown). It is worth noting that addition of z-VAD-fmk itself had no effect on survival or proliferation of RA FLS (Figure 3a and b).
As described above (Figure 2d ), we had observed that TRAIL treatment seems to alter p21 levels in RA FLS. In fact, a recent report correlated the responses of RA FLS to TRAIL, with the expression levels of the cell cycle regulator p21. 15 We therefore analyzed the expression levels of p21
Waf1/Cip1 and of p27 Kip1 , another important cell cycle regulator, in TRAILtreated RA FLS. Expression levels of p21 and p27 were decreased in cells treated for 24 h with TRAIL compared with untreated cells. The level of p21 expression decreased already 6 h after TRAIL exposure (Figure 6a ). It is important that the TRAIL-induced decrease of p21 and p27 was inhibited by the presence of the pan-caspase inhibitor z-VAD-fmk (Figure 6a ). In contrast, inhibitors for PI3-K, ERK and p38 were unable to prevent the TRAIL-dependent degradation of p21 and p27 (Figure 6b ). Using specific inhibitors for caspases 3, 8 and 9, we found different capacities of the respective molecules to block the TRAILmediated reduction of p21 and p27 expression ( Table 1 ). The inhibitor for caspase 8 blocked both p21 and p27 degradation in each of the RA FLS tested, whereas the efficiency of caspase 3 and 9 inhibitors varied between RA FLS from different patients (Table 1 ). In agreement with this, siRNA silencing of caspase 8 was capable to rescue TRAIL-induced p21 and p27 degradation as well (data not shown).
p21 and p27 can be localized in the cytoplasm, as well as in the nucleus. The antibody used for detection of p27 allowed us to detect the cleaved form of p27 at 23 kDa in both the *P <0.05, **P <0.01. n=6 *P <0.05, **P <0.01. n=5 After 48 h cells were treated with 1 nM TRAIL for an additional 24 h and subsequently analyzed for apoptosis and proliferation, as described under Figure 1 . (h) Efficiency of caspase silencing for the respective caspase was verified using western blot analysis. Blots were probed with specific antibodies for either caspase 3, 8 or 9 and subsequently scanned and quantified using NIH image software. Band intensities for the respective caspase were normalized to the corresponding band intensities of control siRNA transfected cells. One representative analysis is shown
The pleiotropic effect of TRAIL is mediated by caspases R Audo et al proliferation. 11 Our finding differs from earlier reports describing that TRAIL has a protective role in the collagen-induced mouse model of arthritis by blocking the proliferation of synovial cells. 16, 17 This discrepancy could reflect the different pathogenic mechanisms between RA in the joints of patients and the respective mouse model. Moreover, the organization of TRAIL signaling between man and mouse seems to be different, as only one membrane-anchored TRAIL receptor and two soluble decoy receptors have been identified in the mouse. 18 We have described that the ERK, p38 and PI3 kinase/Aktsignaling pathways are implicated in TRAIL-induced RA FLS proliferation. 11 In this study, we aimed to further characterize the TRAIL-induced signaling pathways in RA FLS. By using specific protein kinase inhibitors, we found that the PI3 kinase/ Akt-signaling pathway, but not the MAP kinases ERK and p38, protects RA FLS from TRAIL-induced apoptosis. A similar observation has been made in glioblastoma cells by Opel et al. 19 These authors reported that PI3K inhibition significantly enhances apoptosis triggered by TRAIL in glioblastoma cells. 19 Blocking of the PI3 kinase/Akt-signaling pathway in RA FLS was associated with decreased expression of the antiapoptotic proteins Mcl-1, XIAP and RIP and an increased expression of the cell cycle inhibitor p21
Waf1/Cip1 . This finding is in agreement with an earlier report describing that Akt regulates the stability of XIAP, and thus suggesting that XIAP modulates the effect of Akt on cell survival of ovarian cancer cells. 20 Moreover, it has been described that Akt can modulate the activity of p21 and p27 in blocking the cell cycle. 21 Our data indicate that the PI3 kinase inhibitor LY290042 modulates the expression levels of the cell cycle inhibitor p21, and thus sensitizes RA FLS to TRAIL-induced apoptosis. A similar observation was made for bladder and prostate cancer cells, as p21 accumulation sensitized these cells to TRAIL-induced apoptosis. 22 Multiple effects of TRAIL have been earlier reported in human carcinoma cell lines. 23 Low concentrations of TRAIL (1 ng/ml) were found to preferentially induce proliferation in human carcinoma cells. At higher concentrations (100 ng/ml), the situation was more complex, as cell populations responded with either apoptosis, senescence or proliferation. We observed a maximal effect for both apoptosis and proliferation of RA FLS at a TRAIL concentration of 1 nM (20 ng/ml) that was maintained using higher concentrations (up to 10 nM) of TRAIL. TRAIL-induced apoptosis seems not to be a prerequisite for proliferation, as conditioned supernatant taken from apoptotic RA FLS did not induce proliferation when transferred to other cells (data not shown). This is in line with our observation that RA FLS from some patients are nearly resistant to TRAIL-induced apoptosis, but sensitive to TRAIL-induced proliferation (data not shown).
RA FLS express TRAIL receptors 1 and 2, which contain an intracellular cytoplasmic sequence motif, known as the DD.
11
Triggering of TRAIL receptor 1 and 2 results in receptor trimerisation, clustering of the receptor DD and subsequent recruitment of various intracellular molecules, including the dual adapter molecule FADD (Fas-associated DD, also known as Mort1) and the initiator procaspase-8. This complex of interacting proteins is referred to as the death-inducing signaling complex (DISC) because of the original assumption that the main physiological role of FADD-binding death receptors is to trigger apoptosis. However, recent work has shown multiple non-apoptotic activities of these receptors reflecting different signaling components of the DISC.
2 For example, caspases are known to play essential roles in apoptosis and inflammation, but reports are accumulating that caspases can also have other functions. 24, 25 These nonapoptotic functions of caspases can be mediated by both activated caspases as well as by their prodomains. 25 For instance, it is by now well established that caspase 8 has an essential role in lymphocyte proliferation in response to antigen stimulation. 26 Caspase 8 also seems to play a role in cell adhesion and motility. 27 In our study, we found definitive evidence that caspases are at the crux of both TRAIL-induced apoptosis and proliferation of RA FLS, as a pan-caspase inhibitor blocked both cellular responses. The use of specific caspase inhibitors suggested an involvement of caspases 3, 8 and 9 in TRAIL-induced apoptosis, and of caspases 3 and 8 in TRAIL-induced proliferation. This concurs with our earlier described observation that TRAIL induces cleavage of caspases 3, 8 and 9 in RA FLS.
14 Using RNA silencing, we found that caspase 8 is required for both TRAIL-induced apoptosis and proliferation.
Numerous different substrates for caspases have been identified, including kinases. 28 As TRAIL-induced proliferation of RA FLS is mediated by MAP kinases or Akt, we tested whether activation of these kinases is a caspase-dependent process. We could not detect altered activation of MAP kinases or Akt in the presence of a pan-caspase inhibitor, but observed that the inhibitor significantly induced phosphorylation of MAP kinases ERK and p38, as well as Akt in unstimulated RA FLS. As the presence of z-VAD-fmk does not influence survival or proliferation in RA FLS, we conclude that additional signal(s) are required to stimulate their proliferation ( Figure 7) .
It has been reported that caspases can cleave cell-cycle inhibitors such as p21 and p27. 25, 29 Both proteins are involved in the negative regulation of G1/S progression in response to a number of anti-proliferative signals. 30 Here, we describe TRAIL-induced p21 and p27 degradation and report that this degradation is caspase-dependent, as z-VAD-fmk, a pancaspase inhibitor restores initial level of expression. It is of note that TRAIL-triggered degradation of p21 and p27 was not altered by the presence of specific inhibitors for PI3-K, ERK 
RA FLS were stimulated for 24 h with TRAIL (0.5 nM) in the presence of 10 mM of the pancaspase inhibitor (pancasp-In) z-VAD-fmk or specific inhibitors for caspase 3, 8 or 9. Cell lysates were analyzed by immunoblot for p21 and p27 expression. The same blot was stripped and reprobed with a mouse anti-human b-actin antibody and band intensities for p21 and p27 were normalized to the corresponding band intensities for b-actin. Relative efficiency of the respective inhibitor was classified as no rescue (À), partial rescue (+/À) or total rescue (+).
The pleiotropic effect of TRAIL is mediated by caspases R Audo et al and p38 at concentrations that were sufficient to block TRAILinduced proliferation (data not shown and Morel et al. 11 ). Thus, the TRAIL-induced degradation of p21 and p27 in RA FLS seems to be a caspase-dependent event, but independent of ERK, p38 and PI3 kinase/Akt-signaling pathways. Our results suggest that caspases act synergistically with PI3 kinase and/or MAP kinases to mediate TRAIL-induced proliferation in RA FLS. p21 and p27 have been associated with both apoptosis and proliferation, depending on the cell type. 30 We observed that RA FLS cells from certain patients are nearly insensitive to apoptosis when exposed to TRAIL, but responded with increased proliferation when compared with untreated cells (data not shown). RA FLS from these patients therefore represent a rather homogenous cell population according to their modulation by TRAIL. Addition of a pan-caspase inhibitor to these cells decreased TRAIL-induced proliferation and degradation of the cell cycle inhibitors p21 and p27 (data not shown). It therefore seems that decreased expression levels of p21 and p27 favor proliferation in RA FLS. A similar conclusion was earlier drawn by Jungel et al., who described a correlation of p21 expression levels with cell viability in TRAILtreated RA FLS. These authors found that upregulation of p21 induced by trichostatin A, an inhibitor of histone deacetylases, led to cell cycle arrest and decreased proliferation of RA FLS. 15 In line with this finding is our observation that nocodazole-induced cell cycle arrest sensitizes RA FLS for TRAIL-induced apoptosis (data not shown).
In this report, we describe that TRAIL-induced apoptosis and proliferation of RA FLS is mediated by caspases and with a crucial role for caspase 8. The finding that caspase 8 is implicated in TRAIL-induced proliferation in tumor-like RA FLS is to our knowledge the first report associating caspase 8 with proliferation of non-hematopoietic cells.
Materials and Methods
Reagents. Recombinant human TRAIL was purchased from R&D Systems (Lille, France). The specific chemical inhibitors LY294002 (PI3 kinase), PD98059 (ERK1/2) and SB203580 (p38) were purchased from Euromedex (Souffelweyersheim, France), the PI3 kinase inhibitors wortmannin was obtained from Sigma (St Quentin Fallavier, France) and PI-103 from Cayman Chemical (Ann Arbor, MI, USA) and the Akt Inhibitor VIII was obtained from Calbiochem (Meudon, France). All inhibitors were dissolved in DMSO. Pan-caspase inhibitors (z-VAD-fmk or Q-VD-OPH), caspase 3 inhibitor (z-DEVD-fmk), caspase 8 inhibitor (z-IETD-fmk), caspase 9 inhibitor (z-LEHD-fmk) and the caspase control inhibitor (z-FA-fmk, specific for cathepsins B and L) were purchased from R&D Systems (Lille) or from MBL (Woburn, MA, USA) and were dissolved at 20 mM in DMSO. Anti-phospho-Akt was obtained from Cell Signaling (Denver, CO, USA), peroxidase-conjugated secondary antibodies were purchased from Sigma (St Quentin Fallavier) and all other antibodies were obtained from Beckton Dickinson Bioscience Pharmingen (Le Pont-de-Claix, France). The anti-lamin A/C antibody was kindly provided by Dr. Wodrich (CNRS-UMR 5234, Bordeaux, France). The monoclonal antibody 12G10 against anti-alpha-tubulin developed by J Frankel and M Nelson was obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the NICHD and maintained by the University of Iowa.
Preparation of fibroblast-like synoviocytes of rheumatoid arthritis patients. Fibroblasts were isolated from synovium obtained from patients meeting the American College of Rheumatology criteria for RA (revised 1987), who had undergone surgery for synovectomy or total joint replacement surgery. 31 Fresh synovial tissues were broken down and digested in a solution of dispase (2.4 mg/ml) (Gibco, Cergy Pontoise, France), collagenase (250 U/ml) (Sigma) and DNAse (10 000 U/ml) (Calbiochem, Fontenay sous Bois, France). Synovial fibroblasts were cultured in RPMI-1640 supplemented with 10% fetal calf serum (FCS). Cells were used at passage 4-10, when they constitute a homogeneous population of fibroblasts. On reaching confluence, the cells were passaged by brief trypsinization. For experimentation, the FCS in the media was progressively decreased from 10 to 1%, with final starvation for 12 h in RPMI media containing 1% FCS, as described earlier 11 .
Cell proliferation assay. Proliferation was evaluated by measuring DNA synthesis as assessed by incorporation of tritiated [ Western blot analysis. Synovial cells were stimulated with TRAIL at indicated concentrations, and the reaction was stopped by plunging on ice. The cells were washed twice with cold PBS, and lysed with lysis buffer (100 mM Tris, pH 7.4, 100 mM NaCl, 1 mM EDTA, 1 mM NaF, 20 mM NaP 2 O 7 , 2 mM Na 3 VO 4 , 1% Triton X-100, 10% Glycerol, 0.1% SDS and 0.5% desoxycholate) and harvested with a cell scraper. For nuclear extraction experiments, cell were lysed with buffer (10 mM Hepes, 10 mM KCl, 10 mM EDTA, 10O mM DTT and 0.4% IGEPAL) and then centrifuged at 14 000 Â g for 5 min. Pellets containing nuclear fraction were resuspended in lysis buffer. An equal amount of cell lysate was resolved by 10 or 12% polyacrylamide gel and immunoblot was carried out as described earlier. 32 Blots were developed, scanned and densitometric signals were determined using The pleiotropic effect of TRAIL is mediated by caspases R Audo et al
